Emerging Therapeutic Advances in Multiple Sclerosis

Event Time: Wednesday April 30, 2014 2:00 pm to 6:00 pm
Topic(s): MS and CNS Inflammatory Disease
Director(s): Eric Klawiter MD, FAAN, Robert Fox MD, FAAN
Description: In recent years, the FDA has approved three new oral therapies for relapsing remitting multiple sclerosis. There are several other treatments for MS that are in the midst of or have completed phase III clinical trials. Additional emerging therapeutics are currently at varying stages of the drug development pipeline. Faculty will discuss the current treatment options, focusing on efficacy, side effect profiles and risk stratification and monitoring. In a case-based interactive format, faculty will discuss how treatment selection is made in individual patients. Additionally, the session will cover treatment of progressive MS and pediatric MS. The future of treatment, including remyelinating therapies, will also be covered. In addition to didactic sessions, selected abstracts focusing on emerging MS therapeutics will be presented in data-blitz and poster session formats.
Completion Message: Participant should become familiar with new and emerging therapeutics for MS. They should be equipped to improve their management of patients with MS.
CME Credits: 4
Core Competencies:

Ready to register for the 2019 AAN Annual Meeting?

Register Now

Related Courses